About Event
The industry-leading forum focussed on ways to predict, monitor, and mitigate against adverse immune responses to AAV gene therapies.
Successful advancement of gene therapy through clinical trials hinges on the development of robust, clinically validated immunoassays and biodistribution studies. These assays, coupled with real-world data, are instrumental in mitigating efficacy and safety roadblocks that can impede progress and, more critically, jeopardize patient safety.
An in-depth understanding of the of the innate and adaptive immune response, predictable translational models and immunosuppression and modulation strategies to mitigate against adverse responses are vital in developing a safe and effective gene therapy product.
This event was an opportunity to tackle gene therapy immunogenicity in the ‘here and now’ across, 3 days of in-depth case studies, deep-dive workshops and insightful panel discussions.
What You Missed:
Immunogenicity Challenges for Gene Editing
We learned about the unique immunogenicity challenges posed by gene editing therapies from CRISPR Therapeutics and Modalis Therapeutics in our brand-new section dedicated to gene editing
Immune Modulation and Suppression
We heard the latest updates in immune mitigation strategies for local and systemic gene therapies with insights form Spark Therapeutics and Solid Biosciences
Immune Responses to the Therapeutic Gene
Regeneron and Roche reported their latest data from studies into cellular immune responses into the transgene product and disease specific approaches to overcoming immune these reactions
Novel Immunoassays, Bioanalytical and Biodistribution technology
We explored freshly validated assays for T cell quantification and AAV biodistribution with talks from Boehringer Ingelheim and Astellas Gene Therapies
AAV Redosing
We looked into the future of gene therapies and explored AAV redosing through an immunology lens in a deep-dive workshop with The University of Indiana School of Medicine
Event in Numbers
Audience Summary
This summit brought together professionals from preclinical, clinical, translational, bioanalytical, toxicology, and pharmacology development to get the latest insights into overcoming immunogenicity bottlenecks in gene therapy development.
R&D – We discovered and digested the latest and greatest in ensuring the safety and efficacy of gene therapies to gain actionable insights for our delegates' own gene therapy development efforts.
Business Development – We engaged with other business leaders from 40+ industry groups to set up collaborations, secure investment, and unlock future company deals
Service Provider – Our partners positioned themselves as leading vendors in the gene therapy development field and won business. Check out our partnership opportunities here
Academia – Our delegates leveraged the latest data and tech developments from the industry into their own research and network with industry leaders in the field
Testimonials
“If you work on AAV immunogenicity, this meeting is the best place for a direct contact and exchange of ideas with the most relevant colleagues in the gene therapy industry.” Klaudia Kuranda, Head of Immunology, Spark Therapeutics